Medication info
Glita Tablet (Pioglitazone Hydrochloride)

Glita Tablet (Pioglitazone Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Poonglim Pharmaceutical Co., Ltd.
Appearance
White round tablet
Packaging
30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200703230 · Notified 2007.03.19 · Insurance code 649000010

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
This medicine is taken orally once daily, with or without food. Treatment should be continued for an appropriate period to assess changes in glycated hemoglobin (at least 3 months), provided that glycemic control in the patient with diabetes does not worsen further. 1. Monotherapy In patients whose blood glucose is not adequately controlled with diet and exercise, this medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily. If the initial dose of this medicine is not sufficiently effective, the dose may be increased to up to 30 mg once daily. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea. The initial dose in this case is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin. The initial dose in this case is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when combination therapy with this medicine is initiated. However, if a patient receiving this medicine in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to the degree of glycemic control. Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended.
Child dose
Children under 18 years: Administration is not recommended because there is no experience with its use.

Ingredients

Manufacturer
Poonglim Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 diabetes patients
  • blood sugar control disorders
View approved original text

This medication is used as an adjunct to dietary and exercise therapy to enhance blood sugar control in patients with type 2 diabetes. It can be administered as monotherapy, and if there is no improvement in blood sugar after the use of other oral hypoglycemic agents, it may be used in combination with sulfonylureas, metformin, or insulin. Additionally, nutritional counseling, weight loss, and exercise therapy are also important, as they help maintain the effectiveness of the drug therapy not only in initial treatment but also thereafter. Therefore, this medication effectively improves blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

This medicine is taken orally once daily, with or without food. Treatment should be continued for an appropriate period to assess changes in glycated hemoglobin (at least 3 months), provided that glycemic control in the patient with diabetes does not worsen further. 1. Monotherapy In patients whose blood glucose is not adequately controlled with diet and exercise, this medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily. If the initial dose of this medicine is not sufficiently effective, the dose may be increased to up to 30 mg once daily. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea. The initial dose in this case is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin. The initial dose in this case is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when combination therapy with this medicine is initiated. However, if a patient receiving this medicine in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to the degree of glycemic control. Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended.

Child dose

Children under 18 years: Administration is not recommended because there is no experience with its use.

Precautions

This medication helps control blood sugar in patients with type 2 diabetes. It may cause or worsen congestive heart failure in some patients, so symptoms of heart failure, such as weight changes, shortness of breath, and edema, should be closely monitored after starting treatment or increasing doses. This drug should not be used in patients with heart failure or a history of heart failure, and its administration is not recommended in these patients. This medication may cause fluid retention, leading to worsened heart failure when used in combination with other diabetes treatments, so symptoms of heart failure should always be monitored closely. If symptoms such as visible hematuria, urinary issues, or urgent urination arise during the use of this drug, they may indicate bladder cancer, and a doctor should be notified immediately. This medication should not be administered to patients with impaired liver function, severe renal impairment, active bladder cancer, pregnant women, or women of childbearing potential. Patients taking other oral hypoglycemic agents, premenopausal women, patients with edema, patients with heart conditions, and those with kidney dysfunction should use this medication carefully. This drug may cause side effects such as edema, weight gain, headache, upper respiratory infection, and in patients with a history of heart disease, there is an increased risk of developing congestive heart failure. Liver function tests and blood sugar control status should be monitored regularly while on this medication, and hypoglycemic symptoms should be observed. The use of this drug is restricted during pregnancy, and the effects on breastfeeding mothers are not known, so caution is required. It should also be used carefully in the elderly, and appropriate treatment should be given in case of overdose depending on symptoms. The safety and efficacy of this drug in children have not been established.

Side effects

Congestive heart failure, excessive and rapid weight change, shortness of breath, edema, fluid retention, inadequate blood sugar control, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular predisposition, hospitalization due to worsening congestive heart failure, emergency room visit due to congestive heart failure, liver failure, diabetic macular edema accompanied by vision decrease, decreased hemoglobin, decreased hematocrit, elevated serum ALT levels, elevated serum bilirubin levels, fractures, dizziness, loss of appetite, constipation, upper abdominal pain, chest pain, fatigue, weakness, dyspepsia, nausea, cough, itching, chest discomfort, tremor, chills, gastrointestinal disease, abdominal pain, epigastric discomfort, numbness, muscle rigidity, head discomfort, worsening of liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, cardiac failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a container that is well protected from light and air, and in a place that is not humid. The storage temperature should be maintained between 15 and 30 degrees Celsius, preferably around 25 degrees.

Appearance and packaging

Appearance

White round tablet

Package unit

30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.